CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
CytomX Therapeutics (Nasdaq: CTMX) on October 20, 2025 appointed Rachael Lester as Senior Vice President, Chief Business Officer to lead strategy and business development.
The company highlighted Lester’s two decades of experience in corporate strategy, partnerships and capital formation, citing prior roles as chief business officer at Replicate Bioscience, SVP of business development at Harpoon Therapeutics (acquired by Merck), and senior roles at Bruin Biometrics and Onyx Pharmaceuticals. Management said Lester will drive partnering and expand the PROBODY® platform while supporting lead clinical assets CX-2051 and CX-801 aimed at colorectal cancer and melanoma.
CytomX Therapeutics (Nasdaq: CTMX) il 20 ottobre 2025 ha nominato Rachael Lester Senior Vice President, Chief Business Officer per guidare strategia e sviluppo commerciale.
L'azienda ha evidenziato i due decenni di esperienza di Lester in strategia aziendale, partenariati e formazione di capitale, citando precedenti ruoli come chief business officer presso Replicate Bioscience, SVP di sviluppo commerciale presso Harpoon Therapeutics (acquisita da Merck) e ruoli senior presso Bruin Biometrics e Onyx Pharmaceuticals. La direzione ha dichiarato che Lester guiderà le partnership e l'espansione della piattaforma PROBODY® supportando gli asset clinici leader CX-2051 e CX-801 mirati al cancro colorettale e al melanoma.
CytomX Therapeutics (Nasdaq: CTMX) el 20 de octubre de 2025 nombró a Rachael Lester como Vicepresidenta Senior, Chief Business Officer para liderar la estrategia y el desarrollo de negocios.
La empresa destacó los dos décadas de experiencia de Lester en estrategia corporativa, alianzas y formación de capital, citando cargos previos como chief business officer en Replicate Bioscience, SVP de desarrollo de negocios en Harpoon Therapeutics (adquirida por Merck) y puestos de liderazgo en Bruin Biometrics y Onyx Pharmaceuticals. La dirección sostuvo que Lester impulsará las asociaciones y ampliará la plataforma PROBODY® mientras apoya los activos clínicos líderes CX-2051 y CX-801 dirigidos a cáncer colorrectal y melanoma.
CytomX Therapeutics (Nasdaq: CTMX)는 2025년 10월 20일에 Rachael Lester를 수석 부사장, 최고 사업 책임자로 임명하여 전략 및 비즈니스 개발을 주도하게 했습니다.
회사는 Lester의 기업 전략, 파트너십 및 자본 형성 분야에서의 20년 간의 경력을 강조하며 Replicate Bioscience의 최고 비즈니스 책임자, Harpoon Therapeutics(머크에 인수)에서의 비즈니스 개발 수석 부사장, Bruin Biometrics 및 Onyx Pharmaceuticals의 선임 직책 등을 이전 경력으로 들고 있습니다. 경영진은 Lester가 파트너십을 추진하고 PROBODY 플랫폼을 확장하는 한편, 대장암 및 흑색종을 대상으로 하는 주도적 임상 자산 CX-2051 및 CX-801를 지원할 것이라고 밝혔습니다.
CytomX Therapeutics (Nasdaq: CTMX) a nommé le 20 octobre 2025 Rachael Lester au poste de Senior Vice President, Chief Business Officer, pour piloter la stratégie et le développement commercial.
L’entreprise a mis en avant les deux décennies d’expérience de Lester en stratégie d’entreprise, partenariats et formation de capital, citant des postes précédents tels que chief business officer chez Replicate Bioscience, SVP du développement commercial chez Harpoon Therapeutics (acquise par Merck) et des postes à responsabilité chez Bruin Biometrics et Onyx Pharmaceuticals. La direction a déclaré que Lester mènerait les partenariats et étendrait la plateforme PROBODY®, tout en soutenant les actifs cliniques leaders CX-2051 et CX-801 ciblant le cancer colorectal et le mélanome.
CytomX Therapeutics (Nasdaq: CTMX) hat am 20. Oktober 2025 Rachael Lester zur Senior Vice President, Chief Business Officer ernannt, um Strategie und Geschäftsentwicklung zu leiten.
Das Unternehmen hob Lesters zwei Jahrzehnte Erfahrung in Unternehmensstrategie, Partnerschaften und Kapitalbeschaffung hervor und nannte frühere Rollen als Chief Business Officer bei Replicate Bioscience, Senior Vice President der Geschäftsentwicklung bei Harpoon Therapeutics (von Merck übernommen) sowie leitende Positionen bei Bruin Biometrics und Onyx Pharmaceuticals. Die Geschäftsleitung sagte, Lester werde Partnerschaften vorantreiben und die PROBODY-Plattform erweitern, während sie führende klinische Assets CX-2051 und CX-801 unterstützt, die auf Darmkrebs und Melanom abzielen.
CytomX Therapeutics (Nasdaq: CTMX) في 20 أكتوبر 2025 عيّنت راشيل ليستر كـ نائب الرئيس الأول، Chief Business Officer لقيادة الاستراتيجية وتطوير الأعمال.
أبرزت الشركة خبرة ليستر التي امتدت عقدين في الاستراتيجية المؤسسية والشراكات وتكوين رأس المال، مشيرة إلى أدوار سابقة كنائب الرئيس التنفيذي للأعمال في Replicate Bioscience، وكبير مسؤولي تطوير الأعمال في Harpoon Therapeutics (التي اشترتها ميرك)، وأدوار عليا في Bruin Biometrics وOnyx Pharmaceuticals. وقالت الإدارة إن ليستر ستدفع الشراكات وتوسع منصة PROBODY® مع دعم الأصول السريرية الرائدة CX-2051 و CX-801 الموجهة لسرطان القولون والمستقيم والورم الميلانومي.
CytomX Therapeutics (Nasdaq: CTMX) 于 2025年10月20日 任命 Rachael Lester 为高级副总裁、首席商务官，以领导战略与业务发展。
公司强调了 Lester 在企业战略、伙伴关系和资本形成方面的二十年经验，提及其此前担任 Replicate Bioscience 的首席商务官、Harpoon Therapeutics 的商务发展高级副总裁（被默沙东收购）以及 Bruin Biometrics 和 Onyx Pharmaceuticals 的高级职位。管理层表示，Lester 将推动伙伴关系并扩展 PROBODY® 平台，同时支持面向结直肠癌与黑色素瘤的领先临床资产 CX-2051 和 CX-801。
- New CBO hire with 20+ years in BD and strategy
- Led financing and partnerships at Replicate Bioscience during tenure
- Structured major partnerships with AbbVie and Roche at Harpoon
- None.
Leadership team addition to drive strategic long-term value creation and partnering strategy
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company’s strategy and business development functions.
“Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers,” said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. “Rachael’s expertise and leadership in delivering strategic, value-enhancing partnerships will be pivotal as we continue to prosecute our integrated business model and expand the reach of our PROBODY® platform. With her proven track record, Rachael strengthens our leadership team at a critical time for the Company. My colleagues and I look forward to working with Rachael in our collective mission to urgently advance innovative cancer therapies for patients.”
“I’m thrilled to join CytomX at such an exciting time. CytomX’s lead clinical assets, CX-2051 and CX-801, are designed to address areas of high unmet medical need including colorectal cancer and melanoma and have broad potential across many cancer types. I look forward to working with the highly dedicated team at CytomX to further unlock the value of the PROBODY® platform and build on the promise of our pipeline of masked biologics.” said Ms. Lester.
Ms. Lester joins CytomX with over two decades leading corporate strategy, business development and product portfolio planning across the life science and biopharmaceutical industry. Most recently, she was Chief Business Officer at Replicate Bioscience, where she led corporate strategy, business development and capital formation. She was key in securing financing and multiple partnerships to transform the Company during her tenure. Prior to joining Replicate, Ms. Lester served as SVP of Business Development and Corporate Strategy at Harpoon Therapeutics, a novel T cell engager platform company that was later acquired by Merck, where she established and strengthened the business development strategy through major partnerships with AbbVie and Roche. Previously, Ms. Lester held senior roles in corporate strategy, portfolio management, and commercialization at Bruin Biometrics and Onyx Pharmaceuticals, now an Amgen subsidiary. Earlier in her career, she worked in Deloitte and Booz Allen Hamilton’s life sciences consulting practices, where she advised on multi-billion-dollar M&A transactions, new product planning and strategic growth initiatives. Ms. Lester received her M.B.A. from the Kellogg School of Management at Northwestern University and her B.A. in Neuroscience from University of Pennsylvania.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
Who is Rachael Lester and what role did CytomX (CTMX) appoint her to on October 20, 2025?
How does Rachael Lester’s background support CytomX’s strategy for CTMX’s PROBODY® platform?
Which CytomX clinical assets did the company highlight in the October 20, 2025 appointment announcement?
What prior companies and transactions are mentioned in Rachael Lester’s biography for CTMX investors?
Will Rachael Lester lead CytomX’s business development and partnering efforts for CTMX going forward?
Does the October 20, 2025 announcement signal any immediate financial guidance changes for CytomX (CTMX)?
